文献速递基础与转化研究新药、器械与细胞基因治疗研发

基因人源化小鼠模型中丁型肝炎病毒抗病毒联合治疗的临床前评估

Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
PubMed 文献 · Sci Transl Med · 2018-01-01

研究构建了表达人NTCP的转基因小鼠模型,该模型可支持HDV持续感染且依赖HBsAg包装与传播。在免疫缺陷小鼠中病毒血症持续至少80天,免疫健全小鼠14天内清除,显示淋巴细胞对控制HDV感染关键。myrcludex B与lonafarnib单药或联合治疗可有效抑制病毒血症,但在测试剂量下未能治愈HDV感染。

要点

  • hNTCP转基因小鼠可支持HDV持续感染,是研究HDV发病机制与免疫应答的小动物模型。
  • 淋巴细胞对控制HDV感染至关重要,免疫缺陷小鼠病毒血症持续至少80天。
  • myrcludex B与lonafarnib单药或联合可抑制病毒血症,但测试剂量下未能治愈感染。

核心结论

  • 表达人NTCP的转基因小鼠可继承性易感HDV,为研究病毒发病机制、免疫应答及测试新疗法提供机会。
  • myrcludex B与lonafarnib单药或联合治疗在测试剂量下可有效抑制病毒血症但未能治愈HDV感染。

研究设计与样本

  • 构建表达功能性HBV/HDV受体人NTCP的转基因小鼠模型。
  • 在免疫缺陷(缺乏功能性B、T和NK细胞)与免疫健全小鼠中评估HDV感染过程。
  • 测试myrcludex B与lonafarnib单药及联合治疗的抗病毒效果。

主要发现

  • HBV和HDV均以糖蛋白依赖方式进入hNTCP转基因小鼠肝细胞,但HBV复制受进入后阻滞限制。
  • HDV在共表达HBV包膜的hNTCP转基因小鼠中持续感染,符合HDV依赖HBsAg进行包装和传播。
  • 免疫缺陷小鼠病毒血症持续至少80天,免疫健全小鼠14天内清除,表明淋巴细胞对控制HDV感染关键。
  • 急性HDV感染未引起明显肝损伤,但诱导了细胞内在和细胞固有免疫应答。
  • myrcludex B与lonafarnib单药或联合治疗有效抑制病毒血症,但测试剂量下未能治愈HDV感染。

临床怎么用

  • 该模型可用于临床前评估新型HDV疗法及研究病毒发病机制与免疫应答。
  • 联合抗病毒治疗在模型中可抑制病毒血症但未达治愈,提示需优化剂量或联合策略。

局限性

  • HBV在模型中因进入后阻滞未能复制,可能限制对HBV/HDV共感染完整生命周期的模拟。
  • 急性HDV感染未引起明显肝损伤,与人类慢性丁型肝炎的严重肝病表现存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic delta hepatitis, caused by hepatitis delta virus (HDV), is the most severe form of viral hepatitis, affecting at least 20 million hepatitis B virus (HBV)-infected patients worldwide. HDV/HBV co- or superinfections are major drivers for hepatocarcinogenesis. Antiviral treatments exist only for HBV and can only suppress but not cure infection. Development of more effective therapies has been impeded by the scarcity of suitable small-animal models. We created a transgenic (tg) mouse model for HDV expressing the functional receptor for HBV and HDV, the human sodium taurocholate cotransporting peptide NTCP. Both HBV and HDV entered hepatocytes in these mice in a glycoprotein-dependent manner, but one or more postentry blocks prevented HBV replication. In contrast, HDV persistently infected hNTCP tg mice coexpressing the HBV envelope, consistent with HDV dependency on the HBV surface antigen (HBsAg) for packaging and spread. In immunocompromised mice lacking functional B, T, and natural killer cells, viremia lasted at least 80 days but resolved within 14 days in immunocompetent animals, demonstrating that lymphocytes are critical for controlling HDV infection. Although acute HDV infection did not cause overt liver damage in this model, cell-intrinsic and cellular innate immune responses were induced. We further demonstrated that single and dual treatment with myrcludex B and lonafarnib efficiently suppressed viremia but failed to cure HDV infection at the doses tested. This small-animal model with inheritable susceptibility to HDV opens opportunities for studying viral pathogenesis and immune responses and for testing novel HDV therapeutics.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Winer BY, Shirvani-Dastgerdi E, Bram Y, et al. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med. 2018. PMID: 29950446. doi:10.1126/scitranslmed.aap9328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。